Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Measuring the Impact of Carfilzomib and Belatacept on Allogeneic Desensitization in Prospective Kidney Transplant Recipients
NCT05017545Phase 2Active, not recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Dec 2021
- Primary completion
- Feb 2027
- Modality
- Reversible Covalent Inhibitors, Irreversible Covalent Inhibitors, Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of carfilzomib, belatacept in end stage renal disease (ESRD), sponsored by National Institute of Allergy and Infectious Diseases. Started Dec 2021; status: active, not recruiting.
02
Drugs
carfilzomibbelatacept
03
Conditions
end stage renal disease (ESRD)
Beyond the preview
Go deeper on NCT05017545.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05017545.